Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Qiagen's Sample Prep Products, Beckman Coulter's SPRIselect, Bowtie 2, BaseSpace Apps, and more

Premium

Qiagen has launched several sample-prep products for next-generation sequencing, including the Repli-g Single Cell kit, GeneRead rRNA Depletion kit, GeneRead Library Quant kit, and GeneRead DNAseq Gene Panel kits (see related story, this issue).

The Repli-g Single Cell kit makes use of multiple displacement amplification technology, but incorporates the Repli-g polymerase. According to the company, with starting inputs of one to 10 nanograms, the kit yields around 40 micrograms of DNA with average lengths over 10 kilobases. The GeneRead rRNA Depletion kit uses hybrid capture technologies to remove ribosomal RNA.

The kits are compatible with any existing next-generation sequencing technology, as well as Qiagen's other products, and will also be compatible with the next-gen sequencing platform that Qiagen is developing.


Beckman Coulter Life Sciences has launched SPRIselect kit for genomic DNA fragmentation and size selection in library preparation for next-generation sequencing. The kits use Beckman's solid phase reversible immobilization-based chemistry to adjust size distribution between 150 bases and 800 bases. The kits are compatible with Illumina's platforms, Roche's 454 platforms, and Life Technologies' SOLID and Ion Torrent PGM platforms.


Johns Hopkins Bloomberg School of Public Health has released Bowtie 2 version 2.0.1, the first non-beta release, here. The new release of the sequence aligning tool includes fixes for several bugs.


Several firms announced this week that they have added bioinformatics apps to Illumina's BaseSpace applications store. BioMatters has released the Molecular Profiler cloud-based genome browser; DNAStar has launched a de novo bacterial genome assembly app, and Partek has added its Partek Flow app for analysis of RNA-seq, exome, and targeted sequencing data

BaseSpace customers will have free access to all BaseSpace Apps until Jan. 1.


Pacific Biosciences has upgraded its PacBio RS sequencer with new chemistry and software. The so-called XL release is an enhancement to the company's existing C2 chemistry and increases the system's average read length to 5,000 bases from 3,000 bases, with some reads as long as 20,000 bases.
The XL release includes new chemistry with a faster polymerase that reads more bases per second, as well as a feature called Stage Start that produces longer reads by enabling sequence data collection to begin when the polymerase is activated. The company said that it has also increased the length of time the instrument can record data during the sequencing reaction, which also contributes to an increase in read lengths.

BioNano Genomics has launched the Irys genome mapping system, a benchtop instrument that uses the company's IrysChip technology to uncoil and confine long DNA molecules in nanochannel arrays for high-resolution, single-molecule imaging.

Since the system does not require DNA fragmentation or amplification, it can provide sequence information over extremely long regions, ranging from hundreds of kilobases to a megabase, according to the company.

BioNano Genomics said the system allows researchers to directly observe structural variants such as replications, deletions, translocations, and inversions, and that it can analyze several gigabases per hour.


The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.